Is E. coli in urinary tract infections susceptible to fosfomycin?
Yes, E. coli causing urinary tract infections demonstrates excellent susceptibility to fosfomycin, with resistance rates remaining consistently low at approximately 4-5% globally, making it a highly reliable first-line treatment option for uncomplicated cystitis. 1
FDA-Approved Indication and Microbiological Activity
Fosfomycin is FDA-approved specifically for treating uncomplicated UTIs (acute cystitis) in women caused by susceptible strains of E. coli and Enterococcus faecalis 1. The drug demonstrates bactericidal activity in urine at therapeutic doses through irreversible inhibition of bacterial cell wall synthesis, and importantly, there is generally no cross-resistance with other antibiotic classes like beta-lactams or aminoglycosides 1.
Current Susceptibility Data
The evidence overwhelmingly supports high E. coli susceptibility to fosfomycin:
- Overall susceptibility: 96% across 13 countries, with no significant differences between high-income and lower-middle-income settings 2
- European surveillance shows >95% susceptibility in Belgium, Spain, UK, and Russia, with 91.7% in Italy 2
- Recent 2026 data confirms 86% susceptibility among community E. coli isolates 3
- Fosfomycin resistance detected in only 9.5% of uropathogenic E. coli isolates 4
Activity Against Resistant Strains
Fosfomycin maintains excellent activity even against multidrug-resistant E. coli:
- 97% susceptibility among MDR isolates 4
- 84% susceptibility among ESBL-producing strains 4
- 78% susceptibility among carbapenemase-producing isolates 4
Guideline-Recommended Use
Current 2025/2026 guidelines position fosfomycin as a first-line agent for uncomplicated cystitis 5:
Dosing: 3 grams single dose 5
Key advantages:
- Narrow antimicrobial spectrum targeting E. coli and S. saprophyticus
- No collateral damage (minimal disruption of microbiota)
- Currently low resistance rates
- Covers extended-spectrum beta-lactamase (ESBL) and vancomycin-resistant enterococci (VRE) 5
Cure rate: 83-91% for uncomplicated cystitis 5
Important Clinical Caveats
When NOT to Use Fosfomycin
Pyelonephritis: Fosfomycin is NOT indicated for upper tract infections or perinephric abscess 1. While IV fosfomycin may be reasonable for pyelonephritis in some countries, oral fosfomycin lacks strong supporting data for this indication 6
Klebsiella pneumoniae: If K. pneumoniae is suspected, avoid empirical fosfomycin—resistance rates approach 98% in this pathogen 3. This represents a critical prescribing pitfall.
Complicated UTIs: The 2024 guidelines note insufficient evidence for treatment duration in complicated UTIs 6
Risk Factors for Resistance
Age >80 years and ESBL production are significantly associated with increased fosfomycin resistance in E. coli 7. However, even in these populations, susceptibility remains acceptable at 84% for ESBL producers 4.
Pharmacokinetic Considerations
- Mean urine concentration of 706 mcg/mL achieved within 2-4 hours after a 3-gram dose 1
- Urinary concentrations ≥100 mcg/mL maintained for 26 hours 1
- Can be taken without regard to food 1
- 38% recovered unchanged in urine 1
- Renal impairment significantly decreases excretion; half-life increases from 11 to 50 hours in severe renal dysfunction 1
Resistance Surveillance
While fosfomycin resistance remains low, emerging mechanisms include:
- Plasmid-mediated fosA3 gene (detected in 33% of resistant strains) 4
- Mutations in drug transport systems
- Target enzyme modifications 8
Continuous surveillance is essential as resistance can spread through horizontal gene transfer, particularly among MDR strains 8.
Clinical Bottom Line
For uncomplicated cystitis caused by E. coli, fosfomycin represents an excellent empirical choice with 96% susceptibility, single-dose convenience, and minimal ecological impact 5, 2. However, obtain cultures if symptoms persist or recur, as fosfomycin should not be used for treatment failures 1. Never use empirically when K. pneumoniae is suspected based on patient risk factors or local epidemiology 3.